Basilea presents anticancer drug candidate on a symposium in Ireland

Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

Basilea said that the two posters are presented in the late-breaking abstract session, and highlight novel and potentially practice-changing studies, such as ground-breaking and unique data that would not otherwise have been presented at the conference. These posters will show data on the anticancer effects of BAL101553 in combination with eribulin or gemcitabine, which are approved anticancer drugs for the treatment of advanced metastatic breast cancer and pancreatic cancer, respectively.

Dr. Marc Engelhardt, Chief Medical Officer is pleased that the company’s two abstracts have been selected as late-breaking. He explained that the preclinical data show well-tolerated profound synergistic anticancer effects of BAL101553 in combination with the well-established cancer drugs eribulin and gemcitabine, suggesting that such combinations could also be advantageous for patients with advanced metastatic breast cancer and pancreatic cancer.